Virologica Sinica

, Volume 29, Issue 1, pp 17–24 | Cite as

Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies

Review

Abstract

Hepatitis B virus (HBV) infection is still a worldwide health problem; however, the current antiviral therapies for chronic hepatitis B are limited in efficacy. The outcome of HBV infection is thought to be the result of complex interactions between the HBV and the host immune system. While the role of the adaptive immune responses in the resolution of HBV infection has been well characterized, the contribution of innate immune mechanisms remains elusive until recent evidence implicates that HBV appears to activate the innate immune response and this response is important for controlling HBV infection. Here, we review our current understanding of innate immune responses to HBV infection and the multifaceted evasion by the virus and discuss the potential strategies to combat chronic HBV infection via induction and restoration of host innate antiviral responses.

Keywords

HBV innate immunity viral evasion interferon antiviral approaches 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, and Levrero M. 2012. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest, 122: 529–537.PubMedCentralPubMedCrossRefGoogle Scholar
  2. Bertoletti A and Ferrari C. 2012. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut, 61: 1754–1764.PubMedCrossRefGoogle Scholar
  3. Chang J, Block T M, and Guo J T. 2012. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res, 96: 405–413.PubMedCrossRefGoogle Scholar
  4. Chen J, Zhang W, Lin J, Wang F, Wu M, Chen C, Zheng Y, Peng X, Li J, and Yuan Z. 2013. An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases. Mol Ther. doi:10.1038/mt.2013.212.Google Scholar
  5. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, He J, Zheng Y, Chen C, Wang F, Hu Y, Zhou X, Wang C, Xu Y, Lu M, and Yuan Z. 2013. Hepatitis B virus polymerase impairs interferon-alpha-induced STA T activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology, 57: 470–482.PubMedCrossRefGoogle Scholar
  6. Chen Y, Cheng G, and Mahato R I. 2008. RNAi for treating hepatitis B viral infection. Pharm Res, 25: 72–86.PubMedCentralPubMedCrossRefGoogle Scholar
  7. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, and Yuan Z. 2008. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol, 128: 400–408.PubMedCrossRefGoogle Scholar
  8. Cheng J, Imanishi H, Morisaki H, Liu W, Nakamura H, Morisaki T, and Hada T. 2005. Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line, THP-1. J Hepatol, 43: 465–471.PubMedCrossRefGoogle Scholar
  9. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, and Heim M H. 2007. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol, 81: 159–165.PubMedCentralPubMedCrossRefGoogle Scholar
  10. Cooper A, Tal G, Lider O, and Shaul Y. 2005. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol, 175: 3165–3176.PubMedGoogle Scholar
  11. Cradick T J, Keck K, Bradshaw S, Jamieson A C, and McCaffrey A P. 2010. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther, 18: 947–954.PubMedCrossRefGoogle Scholar
  12. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar R M, Brown D, Gilson R J, Tedder R J, Dusheiko G M, Jacobs M, Klenerman P, and Maini M K. 2009. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 137: 1289–1300.PubMedCrossRefGoogle Scholar
  13. Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I, Hartmann G, and Protzer U. 2011. 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology, 141: 696–706, 706 e691–693.PubMedCrossRefGoogle Scholar
  14. Fernandez M, Quiroga J A, and Carreno V. 2003. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol, 84: 2073–2082.PubMedCrossRefGoogle Scholar
  15. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, and Ferrari C. 2009. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut, 58: 974–982.PubMedCrossRefGoogle Scholar
  16. Foster G R, Ackrill A M, Goldin R D, Kerr I M, Thomas H C, and Stark G R. 1991. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A, 88: 2888–2892.PubMedCentralPubMedCrossRefGoogle Scholar
  17. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, and Kremsdorf D. 2001. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol, 75: 2684–2691.PubMedCentralPubMedCrossRefGoogle Scholar
  18. Gruffaz M, Testoni B, Luangsay S, Ait-Goughoulte M, Petit M-A, Ma H, Klumpp K, Javanbakht H, Durantel D, and Zoulim F. 2013. 378 hepatitis B core (hbc) protein is a key and very early negative regulator of the interferon response. Journal of Hepatology, 58: S155–S156.CrossRefGoogle Scholar
  19. Guidotti L G, Rochford R, Chung J, Shapiro M, Purcell R, and Chisari F V. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science, 284: 825–829.PubMedCrossRefGoogle Scholar
  20. Guidotti L G, Morris A, Mendez H, Koch R, Silverman R H, Williams B R, and Chisari F V. 2002. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol, 76: 2617–2621.PubMedCentralPubMedCrossRefGoogle Scholar
  21. Guo H, Jiang D, Ma D, Chang J, Dougherty A M, Cuconati A, Block T M, and Guo J T. 2009. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol, 83: 847–858.PubMedCentralPubMedCrossRefGoogle Scholar
  22. Guy C S, Mulrooney-Cousins P M, Churchill N D, and Michalak T I. 2008. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol, 82: 8579–8591.PubMedCentralPubMedCrossRefGoogle Scholar
  23. Han Q, Zhang C, Zhang J, and Tian Z. 2011. Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS One, 6: e27931.PubMedCentralPubMedCrossRefGoogle Scholar
  24. Han Q, Zhang C, Zhang J, and Tian Z. 2011. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology, 54: 1179–1189.PubMedCrossRefGoogle Scholar
  25. Han Q, Zhang C, Zhang J, and Tian Z. 2013. The role of innate immunity in HBV infection. Semin Immunopathol, 35: 23–38.PubMedCrossRefGoogle Scholar
  26. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning C J, Langenkamp A, Falk C, Buning H, Rose-John S, and Protzer U. 2009. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology, 50: 1773–1782.PubMedCrossRefGoogle Scholar
  27. Isogawa M, Robek M D, Furuichi Y, and Chisari F V. 2005. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol, 79: 7269–7272.PubMedCentralPubMedCrossRefGoogle Scholar
  28. Kosinska A D, Zhang E, Johrden L, Liu J, Seiz P L, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, and Roggendorf M. 2013. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog, 9: e1003391.PubMedCentralPubMedCrossRefGoogle Scholar
  29. Kumar M, Jung S Y, Hodgson A J, Madden C R, Qin J, and Slagle B L. 2011. Hepatitis B Virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol, 85: 987–995.PubMedCentralPubMedCrossRefGoogle Scholar
  30. Kwon H, and Lok A S. 2011. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol, 8: 275–284.PubMedGoogle Scholar
  31. Lan P, Zhang C, Han Q, Zhang J, and Tian Z. 2013. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology, 58: 73–85.PubMedCrossRefGoogle Scholar
  32. Lanford R E, Guerra B, Chavez D, Giavedoni L, Hodara V L, Brasky K M, Fosdick A, Frey C R, Zheng J, Wolfgang G, Halcomb R L, and Tumas D B. 2013. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology, 144: 1508–1517.PubMedCrossRefGoogle Scholar
  33. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, and Mansell A. 2011. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol, 55: 762–769.PubMedCrossRefGoogle Scholar
  34. Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y, and Yuan Z. 2010. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol, 84: 6387–6399.PubMedCentralPubMedCrossRefGoogle Scholar
  35. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X, and Yuan Z. 2013. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nat Immunol, 14: 793–803.PubMedCrossRefGoogle Scholar
  36. Lu H L, and Liao F. 2013. Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol, 191: 3264–3276.PubMedCrossRefGoogle Scholar
  37. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, and Zoulim F. 2009. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 51: 63–72.CrossRefGoogle Scholar
  38. Lutgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann J H, Pollok J M, Lohse A W, Petersen J, and Dandri M. 2011. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology, 140: 2074–2083, 2083 e2071–2072.PubMedCrossRefGoogle Scholar
  39. Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R, Cuconati A, Block T M, Guo J T, and Guo H. 2013. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog, 9: e1003494.PubMedCentralPubMedCrossRefGoogle Scholar
  40. Meng Z, Xu Y, Wu J, Tian Y, Kemper T, Bleekmann B, Roggendorf M, Yang D, and Lu M. 2008. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods, 150: 27–33.PubMedCrossRefGoogle Scholar
  41. Muller C, and Zielinski C C. 1990. Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis. Hepatology, 12: 1118–1124.PubMedCrossRefGoogle Scholar
  42. Nguyen D H, Gummuluru S, and Hu J. 2007. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol, 81: 4465–4472.PubMedCentralPubMedCrossRefGoogle Scholar
  43. Nguyen D H, Ludgate L, and Hu J. 2008. Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol, 216: 289–294.PubMedCrossRefGoogle Scholar
  44. Op den Brouw M L, Binda R S, van Roosmalen M H, Protzer U, Janssen H L, van der Molen R G, and Woltman A M. 2009. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology, 126: 280–289.PubMedCrossRefGoogle Scholar
  45. Pagliaccetti N E, Chu E N, Bolen C R, Kleinstein S H, and Robek M D. 2010. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology, 401: 197–206.PubMedCentralPubMedCrossRefGoogle Scholar
  46. Protzer U, Maini M K, and Knolle P A. 2012. Living in the liver: hepatic infections. Nat Rev Immunol, 12: 201–213.PubMedCrossRefGoogle Scholar
  47. Rang A, Gunther S, and Will H. 1999. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol, 31: 791–799.PubMedCrossRefGoogle Scholar
  48. Revill P, and Yuan Z. 2013. New insights into how HBV manipulates the innate immune response to establish acute and persistent infection. Antivir Ther, 18: 1–15.PubMedCrossRefGoogle Scholar
  49. Robek M D, Boyd B S, and Chisari F V. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J Virol, 79: 3851–3854.PubMedCentralPubMedCrossRefGoogle Scholar
  50. Turelli P, Mangeat B, Jost S, Vianin S, and Trono D. 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science, 303: 1829.PubMedCrossRefGoogle Scholar
  51. Vincent I E, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U, and Chemin I. 2011. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One, 6: e26315.PubMedCentralPubMedCrossRefGoogle Scholar
  52. Visvanathan K, Skinner N A, Thompson A J, Riordan S M, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, and Locarnini S. 2007. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology, 45: 102–110.PubMedCrossRefGoogle Scholar
  53. Wang H, and Ryu W S. 2010. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog, 6: e1000986.PubMedCentralPubMedCrossRefGoogle Scholar
  54. Wang Q, Zhou J, Zhang B, Tian Z, Tang J, Zheng Y, Huang Z, Tian Y, Jia Z, Tang Y, van Velkinburgh J C, Mao Q, Bian X, Ping Y, Ni B, and Wu Y. 2013. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog, 9: e1003410.PubMedCentralPubMedCrossRefGoogle Scholar
  55. Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, and Yuan Z. 2013. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol, 190: 5142–5151.PubMedCrossRefGoogle Scholar
  56. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Wang Y, Wen C, Wu Q, Shi W, and Zhong H. 2010. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol, 185: 1158–1168.PubMedCrossRefGoogle Scholar
  57. Wieland S, Thimme R, Purcell R H, and Chisari F V. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A, 101: 6669–6674.PubMedCentralPubMedCrossRefGoogle Scholar
  58. Wieland S F, Guidotti L G, and Chisari F V. 2000. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol, 74: 4165–4173.PubMedCentralPubMedCrossRefGoogle Scholar
  59. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, and Schlaak J F. 2007. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology, 46: 1769–1778.PubMedCrossRefGoogle Scholar
  60. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa J P, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, and Schlaak J F. 2009. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology, 49: 1132–1140.PubMedCrossRefGoogle Scholar
  61. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, and Yuan Z. 2009. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol, 46: 2640–2646.PubMedCrossRefGoogle Scholar
  62. Yu S, Chen J, Wu M, Chen H, and Yuan Z. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol, 91: 2080–2090.PubMedCrossRefGoogle Scholar
  63. Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain M M, Balschun K, Rocken C, Arlt A, Gunther R, Hampe J, Schreiber S, Baron J L, Moody D B, Liang T J, and Blumberg R S. 2012. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med, 18: 1060–1068.PubMedCentralPubMedCrossRefGoogle Scholar
  64. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak J F, Roggendorf M, and Lu M. 2012. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol, 57: 522–528.PubMedCrossRefGoogle Scholar
  65. Zimmerman K A, Fischer K P, Joyce M A, and Tyrrell D L. 2008. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol, 82: 8013–8021.PubMedCentralPubMedCrossRefGoogle Scholar
  66. Zoulim F. 2012. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res, 96: 256–259.PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Key Laboratory of Medical Molecular Virology, Ministry of Education and Ministry of HealthShanghai Medical College of Fudan UniversityShanghaiChina

Personalised recommendations